References analysis of the Wikipedia article "다발성 골수종" in the Korean version

cancer.org

“Survival Rates for Multiple Myeloma”. 《American Cancer Society》. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

“Drug Therapy for Multiple Myeloma”. 《American Cancer Society》. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

doi.org

dx.doi.org

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (July 2009). “Multiple myeloma”. 《Lancet》 374 (9686): 324–39. doi:10.1016/S0140-6736(09)60221-X. PMID 19541364.

Georgakopoulou R, Fiste O, Sergentanis TN, Andrikopoulou A, Zagouri F, Gavriatopoulou M, 외. (September 2021). “Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses”. 《Journal of Clinical Medicine》 10 (18): 4179. doi:10.3390/jcm10184179. PMC 8469366. PMID 34575290.

De Roos AJ, Spinelli J, Brown EB, Atanackovic D, Baris D, Bernstein L, 외. (November 2018). “Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma”. 《Occupational and Environmental Medicine》 75 (11): 798–806. doi:10.1136/oemed-2018-105154. PMC 9386620. PMID 30121582.

van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S (May 2016). “Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma”. 《International Journal of Laboratory Hematology》 38 (Suppl 1): 110–122. doi:10.1111/ijlh.12504. PMID 27161311.

Global Burden of Disease Study 2013, Collaborators (2015년 8월 22일). “Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.”. 《Lancet (London, England)》 386 (9995): 743–800. doi:10.1016/s0140-6736(15)60692-4. PMC 4561509. PMID 26063472.

GBD 2013 Mortality and Causes of Death, Collaborators (2015년 1월 10일). “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.”. 《Lancet (London, England)》 385 (9963): 117–71. doi:10.1016/s0140-6736(14)61682-2. PMC 4340604. PMID 25530442.

International Myeloma Working Group (June 2003). “Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group”. 《British Journal of Haematology》 121 (5): 749–757. doi:10.1046/j.1365-2141.2003.04355.x. PMID 12780789. S2CID 3195084.

Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S, 외. (September 2012). “Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells”. 《Blood》 120 (13): 2620–2630. doi:10.1182/blood-2011-04-347484. PMC 3460684. PMID 22517906.

Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, 외. (September 1998). “Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution”. 《Archives of Internal Medicine》 158 (17): 1889–1893. doi:10.1001/archinte.158.17.1889. PMID 9759684.

Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J (October 1994). “Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group”. 《European Journal of Haematology》 53 (4): 207–212. doi:10.1111/j.1600-0609.1994.tb00190.x. PMID 7957804. S2CID 2861880.

Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, 외. (March 2013). “The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis”. 《Kidney International》 83 (3): 463–470. doi:10.1038/ki.2012.414. PMID 23302715.

Castillo JJ (December 2016). “Plasma Cell Disorders”. 《Primary Care》 43 (4): 677–691. doi:10.1016/j.pop.2016.07.002. PMID 27866585.

Blimark, Cecilie (January 2015). “Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients”. 《Haematologica》 100 (1): 107–113. doi:10.3324/haematol.2014.107714. PMC 4281323. PMID 25344526.

Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C, 외. (March 1995). “Immunological factors and risk of infection in plateau phase myeloma”. 《Journal of Clinical Pathology》 48 (3): 260–266. doi:10.1136/jcp.48.3.260. PMC 502468. PMID 7730490.

Shah A, Ali A, Latoo S, Ahmad I (June 2010). “Multiple Myeloma presenting as Gingival mass”. 《Journal of Maxillofacial and Oral Surgery》 9 (2): 209–212. doi:10.1007/s12663-010-0050-7. PMC 3244103. PMID 22190790.

Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, 외. (May 2009). “Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study”. 《Blood》 113 (22): 5412–5417. doi:10.1182/blood-2008-12-194241. PMC 2689042. PMID 19179464.

Dutta AK, Hewett DR, Fink JL, Grady JP, Zannettino AC (July 2017). “Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma”. 《British Journal of Haematology》 178 (2): 196–208. doi:10.1111/bjh.14649. PMID 28466550.

Willrich MA, Murray DL, Kyle RA (January 2018). “Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma”. 《Clinical Biochemistry》 51: 38–47. doi:10.1016/j.clinbiochem.2017.05.001. PMID 28479151.

Roberts DL, Dive C, Renehan AG (2010). “Biological mechanisms linking obesity and cancer risk: new perspectives”. 《Annual Review of Medicine》 61: 301–316. doi:10.1146/annurev.med.080708.082713. PMID 19824817.

Koura DT, Langston AA (August 2013). “Inherited predisposition to multiple myeloma”. 《Therapeutic Advances in Hematology》 4 (4): 291–297. doi:10.1177/2040620713485375. PMC 3734900. PMID 23926460.

Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, 외. (October 2016). “Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium”. 《British Journal of Haematology》 175 (1): 87–101. doi:10.1111/bjh.14199. PMC 5035512. PMID 27330041.

Sergentanis TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, Dimopoulos MA, Psaltopoulou T (October 2015). “Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses”. 《Clinical Lymphoma, Myeloma & Leukemia》 15 (10): 563–577.e3. doi:10.1016/j.clml.2015.06.003. PMID 26294217.

Rezk SA, Zhao X, Weiss LM (September 2018). “Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update”. 《Human Pathology》 79: 18–41. doi:10.1016/j.humpath.2018.05.020. PMID 29885408. S2CID 47010934.

Yan J, Wang J, Zhang W, Chen M, Chen J, Liu W (April 2017). “Solitary plasmacytoma associated with Epstein-Barr virus: a clinicopathologic, cytogenetic study and literature review”. 《Annals of Diagnostic Pathology》 27: 1–6. doi:10.1016/j.anndiagpath.2016.09.002. PMID 28325354.

Dojcinov SD, Fend F, Quintanilla-Martinez L (March 2018). “EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts”. 《Pathogens》 7 (1): 28. doi:10.3390/pathogens7010028. PMC 5874754. PMID 29518976.

Rajkumar, S. Vincent (2012년 12월 8일). “Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?”. 《Hematology. American Society of Hematology. Education Program》 2012: 354–361. doi:10.1182/asheducation.V2012.1.354.3798330. PMID 23233604. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

Rubinstein, Samuel M. (2020년 1월 28일). “Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content”. 《JCO Clinical Cancer Informatics》 4 (4): 60–70. doi:10.1200/CCI.19.00122. PMC 7000232. PMID 31990580.

nih.gov

ncbi.nlm.nih.gov

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (July 2009). “Multiple myeloma”. 《Lancet》 374 (9686): 324–39. doi:10.1016/S0140-6736(09)60221-X. PMID 19541364.

Castillo JJ (December 2016). “Plasma Cell Disorders”. 《Primary Care》 43 (4): 677–691. doi:10.1016/j.pop.2016.07.002. PMID 27866585.

Chapel HM, Lee M (July 1994). “The use of intravenous immune globulin in multiple myeloma”. 《Clinical and Experimental Immunology》 97 (Suppl 1): 21–24. PMC 1550368. PMID 8033429.

Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, 외. (2015). “Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature”. 《International Journal of Clinical and Experimental Pathology》 8 (2): 2090–2102. PMC 4396324. PMID 25973110.

semanticscholar.org

api.semanticscholar.org

web.archive.org

“Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment”. 《National Cancer Institute》. 1980년 1월 1일. 2021년 1월 9일에 원본 문서에서 보존된 문서. 2017년 11월 28일에 확인함.

Ferri FF (2013). 《Ferri's Clinical Advisor 2014 E-Book: 5 Books in 1》. Elsevier Health Sciences. 726쪽. ISBN 978-0-323-08431-4. 2023년 8월 18일에 원본 문서에서 보존된 문서. 2020년 8월 23일에 확인함.

“Multiple Myeloma: Statistics”. 《ASCO Cancer.net》. March 2023. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

“Cancer Stat Facts: Myeloma”. 《National Cancer Institute》. 2020년 5월 7일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

“Survival Rates for Multiple Myeloma”. 《American Cancer Society》. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

“International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma”. 《International Myeloma Foundation》. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 11일에 확인함.

“Hypercalcemia”. 《The Lecturio Medical Concept Library》. 2021년 7월 25일에 원본 문서에서 보존된 문서. 2021년 8월 11일에 확인함.

“Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0” (PDF). 《U.S. Dept. of Health and Human Services》. 2017년 11월 27일. 2023년 5월 19일에 원본 문서 (PDF)에서 보존된 문서. 2023년 6월 12일에 확인함.

Lancman, Guido (2022년 11월 15일). “Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies”. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 11일에 확인함.

“Diagnosis of multiple myeloma”. 《Canadian Cancer Society》. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 11일에 확인함.

“Rudhiram Hematology Clinic—Google Search”. 《www.google.com》. 2023년 4월 1일에 원본 문서에서 보존된 문서. 2022년 2월 4일에 확인함.

“Drug Therapy for Multiple Myeloma”. 《American Cancer Society》. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

“What Is DARZALEX®?”. 2021년 4월 9일. 2023년 6월 11일에 원본 문서에서 보존된 문서. 2023년 6월 10일에 확인함.

worldcat.org

Rajkumar SV (2018). 〈Multiple Myeloma〉. Hensley ML, Milowsky MI, Rajkumar SV, Schuetze SM. 《ASCO-SEP : Medical Oncology Self-Evaluation Program》 7판. Alexandria, VA: American Society of Clinical Oncology. ISBN 978-0-9983747-4-1. OCLC 1080368315.

Glick M (January 2015). Glick M, 편집. 《Burket's oral medicine》. PMPH USA. ISBN 978-1-60795-188-9. OCLC 888026338.

다발성 골수종 (Korean Wikipedia)

ashpublications.org

books.google.com

cancer.ca

cancer.gov

cancer.gov

seer.cancer.gov

ctep.cancer.gov

cancer.net

cancer.org

darzalex.com

doi.org

dx.doi.org

google.ca

books.google.ca

google.com

lecturio.com

medigatenews.com

myeloma.org